art-stent.com Report : Visit Site

Technical data of the art-stent.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host art-stent.com. Currently, hosted in France and its service provider is OVH SAS .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

toggle navigation product technology about news contact natural healing through pure resorption™ product technology product art is a leading innovator in the field of the next generation of fully bioresorbable scaffolds (brs) that promote the natural remodeling of an injured artery after vascular angioplasty art pbs scaffold the art pure bioresorbable scaffold (pbs) is providing effective scaffolding followed by programmed dismantling at around 3 months to enable positive remodeling and complete resorption within 24 months. procedure the art pbs is expanded following balloon pre-dilatation of a vascular lesion. after an effective scaffolding period of 3 months, the scaffold dismantles and releases the artery before it completely resorbs. clinical data the art pbs has been investigated in the multicenter artdiva trial and shown proven scaffolding properties with only 4.3 % angiographic recoil and good drug free brs long term performances. art’s unique proprietary polymer provides a versatile platform for vascular scaffolding technology a disruptive new technology for the treatment of coronary and peripheral arterial disease core technology unique, proprietary pla platform technology with tunable dismantling, material preserving transformation processes with precise and secure crimping. healthy healing effective scaffolding followed by programmed dismantling at around 3 months to enable positive remodeling and safe complete resorption within 24 months. in vitro data state of the art in vitro assay development and characterization equipment enhanced strong supportive data for every stage of the bioresorption process. in vivo data extensive preclinical trial track record with proven safety data from dual glp animal model investigations with > 250 implantations and up to 36 months follow up. about art is a leading innovator in the field of the next generation of fully bioresorbable scaffolds (brs) that promote the natural remodeling of an injured artery after vascular angioplasty bioresorbable scaffolds are the 4th generation pci key milestones pr. lafont, interventional cardiologist, and pr. vert, world leading expert in bioresorbable polymers, meet and decide after initial academic research to found art. pre 2008, art focuses efforts on the exploration of various bioresorbable pla formulas and scaffold concepts. from 2009 to 2011 development of art’s first generation bioresorbable scaffold art pbs, for the most clinically, technically and regulatory demanding indication: coronary angioplasty. development plans were established in collaboration with world leading independent experts like, dr virmani, dr popma and dr fajadet. 2012 first implantation on human in toulouse by dr fajadet. 2014 art signs structured buyout agreement with terumo, validating art’s next-gen bioresorbable scaffold. 2015 art receives ce mark approval for its drug free art pbs device. machiel van der leest ceo / director machiel as a seasoned medical device professional and entrepreneur has developed and introduced over 10 class iii devices in the european and global interventional coronary and neurovascular market. in his 15+ years career machiel held executive positions as cto and cso at nycomed amersham medical systems, cathnet science and he co-founded minvasys. his decisive focus on managing innovation combined with his strong track record, have been the driving forces behind art since 2009. machiel holds a msc degree from the technical university delft, netherlands, and he is an inventor of over 20 patents. sophie humbert coo sophie is a driven and structured manager and has successfully taken several medical devices from development, through ce marking, to sales. before joining art in 2014, with her 13 years experience, sophie held executive positions as cso and ceo at medtech start-ups, where she launched innovative devices on the market, expanded sales in europe and established successful industrial and academic partnerships. results-oriented, her strong track record is a key to bring art to success. sophie holds a phd in pharmaceutical sciences from the university of geneva, switzerland. -- partners founders pr. antoine lafont pr. lafont is interventional cardiologist at georges pompidou hospital, professor at paris descartes university, and co-founder of eapci (esc). he identified in 1991 the role of arterial remodeling in the healing process post angioplasty during his post-doctoral fellowship at the cleveland clinic where he met with dr. cornhill, and performed his phd thesis with pr. vert on the selection of polylactic acids for arterial scaffolds after his return in france. pr. michel vert pr. vert founded the laboratory of macromolecular substances at the insa rouen in 1981. in 1991, he created the joint cnrs university montpelier unit devoted to polymeric biomaterials, biology and health. pr. vert is the author of 330 articles, book chapters and is an inventor on many patents. he cofounded several med- and biotech’s. he received awards as “jungfleish” grand prix of the french academy of sciences in 2001 and grand prix georges winter of the european society for biomaterials in 2005. dr. frederick cornhill dr. cornhill is the co-director of the minimally invasive new technology (mint) program at new york presbyterian and weill cornell medical center. dr. cornhill was the founding chairman of the department of biomedical engineering at the cleveland clinic and the founding director of the institute for biomedical engineering at the university of oxford. dr. cornhill founded a number of medical technology companies and served on the board of several medical technology startups. board -- eric viaud chairman eric, co-founder, chairman and ceo of gene signal, has spent more than 20 years in the medical and pharmaceutical industries (basf, synthelabo, medtronic) working in the areas of reimbursement, development, licensing, marketing and sales in france, uk, germany and switzerland. eric has successfully overseen and led the development of several biotech start-up ventures. he is an advisor and board member of several biotech companies in europe. -- philippe boucheron director philippe is co-founder of bioam investment fund. as deputy director of health investment and branch office at bpifrance investment committee, he is now member of the supervisory boards of several biotech and medtech companies. philippe holds a national institute of engineering degree in applied science in biochemical engineering and microbial genetics, a msc degree in biochemical engineering from the polytechnic school of montreal and an mba from insead. -- philippe dhamelincourt director philippe is co-founder and chairman of matignon investissement & gestion. philippe has been involved in venture capital investment for nearly 40 years. after arthur andersen, philippe joined the simer as cfo for the french, african & asian activities. he joined the worms bank in 1978 and became ceo of acmer, and then director in of the participations and investments department. philippe holds a mba from the paris escp business school. -- olivier motte director olivier is ceo of turenne capital, a private equity company with roughly 500 m€ of aum. previously, olivier was responsible for the corporate market for the commercial and investment division of hsbc france. olivier is also ceo of de baecque beau bank, branch of hsbc group. he holds a mba from hec and a master degree from université paris dauphine. news promising pre-clinical data on the next generation drug eluting bioresorbable scaffold paris, france, may 21 2015 — terumo and arterial remodeling technologies (art) announce that, on may 20, 2015, dr renu virmani, internationally renowned cardiovascular pathologist at cvpath institute, usa, presented promising pre-clinical data on terumo’s next generation drug eluting bioresorbable scaffold for the treatment of coronary artery disease. “we are particularly satisfied with the well […] -- art announce

URL analysis for art-stent.com

http://art-stent.com/?p=245
http://art-stent.com/?p=300
http://art-stent.com/www.iseabloom.com
http://art-stent.com/?p=59
http://art-stent.com/?p=56
http://art-stent.com/?p=284
http://art-stent.com/?p=279
http://art-stent.com/?p=52
http://art-stent.com/?p=256
http://art-stent.com/#works
http://art-stent.com/#carousel-homepage-latestnews
http://art-stent.com/#focus
http://art-stent.com/#contact
http://art-stent.com/?p=63
http://art-stent.com/?p=295

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: ART-STENT.COM
Registry Domain ID: 1256553970_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.ovh.com
Registrar URL: http://www.ovh.com
Updated Date: 2015-09-07T07:42:07Z
Creation Date: 2007-10-05T14:21:26Z
Registry Expiry Date: 2018-10-05T14:21:26Z
Registrar: OVH
Registrar IANA ID: 433
Registrar Abuse Contact Email:
Registrar Abuse Contact Phone:
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: DNS200.ANYCAST.ME
Name Server: NS200.ANYCAST.ME
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-09-23T17:06:20Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR OVH

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =art-stent.com

  PORT 43

  TYPE domain

DOMAIN

  NAME art-stent.com

  CHANGED 2015-09-07

  CREATED 2007-10-05

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  DNS200.ANYCAST.ME 46.105.206.200

  NS200.ANYCAST.ME 46.105.207.200

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .